Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...